Plantainoside D

Plantainoside D, a phenylethanoid glycosides, is a IKK-β inhibitor with diverse biological activities. Plantainoside D shows inhibitory activity of angiotensin-converting enzyme (ACE) with an IC₅₀ of 2.17 mM. Plantainoside D significantly reduces the release of glutamate from nerve terminals in the cerebral cortex of rats by inhibiting the voltage-dependent calcium channel (VDCCs) and protein kinase C (PKC) signaling cascade. Plantainoside D significantly alleviates cell apoptosis by inhibiting the generation of ROS and the activation of NF-κB. Plantainoside D significantly improves acute lung injury (ALI) induced by sepsis by regulating the Sirt3/NLRP3 signaling pathway. Plantainoside D can be used for the study of neuroprotection, antioxidant, anti-inflammation, antihypertension^{[1][2][3][4][5][6]}. In Vitro:Plantainoside D (0-50 μM, 10 min) significantly inhibits the release of glutamate induced by 4-aminopyridine (4-AP) (HY-B0604) via vesicle exocytosis pathway with an IC₅₀ of 32 μM in rat synaptosome^[1].
Plantainoside D (30 μM, 10 min) reduces the Ca²⁺ influx induced by 4-AP through N-type calcium channels, and does not alter the membrane potential in rat synaptosome^[1].
Plantainoside D (30 μM, 20 min) acts through PKC-α/SNAP-25 phosphorylation as its key downstream mechanism in rat synaptosome^[1].
Plantainoside D (5 μM, 24 h) significantly improves sepsis induced ALI by regulation of Sirt3/NLRP3 pathway in MLE-12 cells^[2].
Plantainoside D (1-20 μg/mL, 1-4 h) significantly reduces the apoptosis induced by Doxorubicin (ADR) (HY-15142A) by inhibiting the generation of ROS and the activation of NF-κB^[3].
Plantainoside D exhibits weak inhibitory effects of CYP1A2 (IC₅₀ = 12.83 μM), CYP2D6 (IC₅₀ = 8.39 μM) and CYP3A4 (IC₅₀ = 14.66 μM)^[4].
In Vivo:Plantainoside D (50 mg/kg, i.p., once daily for 7 days) significantly improves sepsis induced ALI by regulation of Sirt3/NLRP3 pathway in mice^[2].